Press Releases BeiGene, Ltd.

Equities

BGNE

US07725L1026

Market Closed - Nasdaq Other stock markets 02:00:01 04/05/2024 am IST			5-day change	1st Jan Change
162.2 ^USD	+0.15%		+5.65%	-10.04%

02/05	Amgen Posts Higher 1Q Revenue, Swings to Loss	DJ
23/04	Sector Update: Health Care Stocks Rise in Afternoon Trading	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BeiGene : Financial Information - Form 8-K	26/04	PU
BeiGene Demonstrates Global Progress in 2023 Responsible Business & Sustainability Report	26/04	BU
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	25/04	BU
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04	BU
BeiGene Receives FDA Approval for TEVIMBRA for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma after Prior Chemotherapy	15/03	AQ
BeiGene Receives FDA Approval for TEVIMBRA® for the Treatment of Advanced or Metastatic Esophageal Squamous Cell Carcinoma After Prior Chemotherapy	15/03	BU
First Doses of BRUKINSA provided to Patients with Chronic Lymphocytic Leukemia in Low and Middle-Income Countries under Collaboration of the Max Foundation, BeiGene, and the BeiGene Foundation	14/03	AQ
First Doses of BRUKINSA® provided to Patients with Chronic Lymphocytic Leukemia in Low- and Middle-Income Countries Under Collaboration of The Max Foundation, BeiGene, and the BeiGene Foundation	13/03	BU
BRINGING LIGHT TO THE DARKNESS OF CANCER, BEIGENE NAMED NATIONAL PARTNER OF SURVIVORSHIP AND HOPE FOR THE LEUKEMIA & LYMPHOMA SOCIETY'S LIGHT THE NIGHT	13/03	AQ
BeiGene : Material Event - Form 8-K	08/03	PU
BeiGene Announces FDA Accelerated Approval of BRUKINSA for the Treatment of Relapsed or Refractory Follicular Lymphoma	08/03	BU
BeiGene to Present Clinical and Preclinical Data from Broad Portfolio and Pipeline at AACR Annual Meeting 2024	06/03	BU
New BeiGene Head of Europe, Global Clinical Operations appointed	05/03	AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	01/03	AQ
BeiGene Announces New Efficacy Analysis Comparing BRUKINSA® vs Acalabrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia	29/02	BU
BeiGene to Present at Upcoming Investor Conferences	28/02	BU
BeiGene's Biologics License Application for TEVIMBRA for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA	28/02	AQ
BeiGene’s Biologics License Application for TEVIMBRA® (tislelizumab) for First-Line Gastric or Gastroesophageal Junction Cancers Accepted by FDA	27/02	BU
BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates	26/02	BU
BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	26/02	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BeiGene, Ltd.

Equities

BGNE

US07725L1026

Press Releases

Filters